Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04314375
PHASE4

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

Sponsor: Bausch Health Americas, Inc.

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, placebo-controlled, multicenter, study to evaluate the efficacy, safety, and pharmacokinetics (PK) of budesonide extended-release tablets for the induction of remission in pediatric subjects, with active, mild to moderate ulcerative colitis (UC). Subjects will be permitted to continue taking background oral or rectal 5-aminosalicylate (5-ASA) products.

Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets n Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

Key Details

Gender

All

Age Range

5 Years - 17 Years

Study Type

INTERVENTIONAL

Enrollment

70

Start Date

2023-09-29

Completion Date

2027-06

Last Updated

2025-09-16

Healthy Volunteers

No

Interventions

DRUG

Low Dose Budesonide

3 milligrams once daily for ages 5 to 11 years 11 months. 6 milligrams once daily for ages 12 to 17 years.

DRUG

High Dose Budesonide

6 milligrams once daily for ages 5 to 11 years 11 months. 9 milligrams once daily for ages 12 to 17 years.

DRUG

Placebo

Matching placebo once daily.

Locations (4)

Bausch Health Site 008

Garden Grove, California, United States

Bausch Health Site 003

Indianapolis, Indiana, United States

Bausch Health Site 006

The Bronx, New York, United States

Bausch Health Site 010

Greenville, North Carolina, United States